Arrowstreet Capital’s Ascendis Pharma A/S ASND Stock Holding History

Arrowstreet Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.5M	Buy	125,772 +34,302	+38%	+$8.01M	0.01%	700
2026 Q1	$20.9M	Buy	+91,470	New	+$20.5M	0.01%	739
2025 Q4	–	Sell	-60,658	Closed	-$12.1M	–	1828
2025 Q3	$12.1M	Buy	+60,658	New	+$11.3M	0.01%	901
2023 Q1	–	Sell	-29,218	Closed	-$3.57M	–	1342
2022 Q4	$3.57M	Buy	+29,218	New	+$3.39M	0.01%	753
2022 Q3	–	Sell	-13,105	Closed	-$1.22M	–	1262
2022 Q2	$1.22M	Buy	13,105 +11,085	+549%	+$1.04M	﹤0.01%	892
2022 Q1	$237K	Buy	+2,020	New	+$234K	﹤0.01%	1106
2020 Q2	–	Sell	-3,500	Closed	-$394K	–	2284
2020 Q1	$394K	Buy	+3,500	New	+$455K	﹤0.01%	1575
2019 Q4	–	Sell	-13,700	Closed	-$1.32M	–	1723
2019 Q3	$1.32M	Buy	+13,700	New	+$1.53M	﹤0.01%	1094
2019 Q1	–	Sell	-25,799	Closed	-$1.62M	–	1714
2018 Q4	$1.62M	Buy	25,799 +5,484	+27%	+$345K	﹤0.01%	853
2018 Q3	$1.44M	Sell	20,315 -8,637	-30%	-$595K	﹤0.01%	732
2018 Q2	$1.93M	Buy	+28,952	New	+$1.9M	﹤0.01%	696

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Arrowstreet Capital's ASND Position: Q2 2026 in Review

Arrowstreet Capital increased its Ascendis Pharma A/S (ASND) stake by 38% in Q2 2026, buying an estimated $8.01M and bringing the position to 125,772 shares worth $33.5M. The position accounts for 0.01% of the portfolio, ranked #700.

Arrowstreet Capital first reported a position in ASND in Q2 2018 and has held it in 11 quarters since. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Arrowstreet Capital held 125,772 shares of Ascendis Pharma A/S worth $33.5M as of Q2 2026.
Arrowstreet Capital bought 34,302 Ascendis Pharma A/S shares in Q2 2026, an estimated $8.01M.
Ascendis Pharma A/S made up 0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #700 holding.
Arrowstreet Capital first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 11 quarters since.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.